Biotech Stock Hits 3-Year Highs on Trial Results

Candel Therapeutics Inc (NASDAQ:CADL) is soaring today, up 164% at $12.17 at last glance and earlier hitting a three-year high of $14.60, after the biotech company's prostate cancer immunotherapy treatment, CAN-2409, met its goal in a late-stage study. Combined with radiation therapy, it significantly improved the time patients lived without signs or symptoms of the cancer. On the charts, CADL inched above its mid-May peak to mark its highest levels since September 2021. And before today, the 320-day moving ...